Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

With IPCALAB's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 2.627000
forwardPE 25.514326
debtToEquity 16.246000
earningsGrowth 0.136000
revenueGrowth 0.105000
grossMargins 0.689190
operatingMargins 0.146320
trailingEps 29.080000
forwardEps 47.850000

Ipca Laboratories Limited's current ratio of 2.627, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as Ipca Laboratories Limited has enough cash and current assets to handle its immediate liabilities comfortably.
Ipca Laboratories Limited's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
IPCALAB's low Debt-to-Equity ratio shows the company avoids heavy reliance on debt. This balanced approach reduces financial risk, as it maintains a healthy equity position without excessive leverage, providing greater financial stability and flexibility.
Positive earnings and revenue growth for IPCALAB suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
Ipca Laboratories Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Ipca Laboratories Limited's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


1 IPCALAB stock sales were completed, with market price of 1513.199951171875.During the period under consideration, no sell transactions took place.IPCALAB is seeing more buys than sells at current price levels, which may indicate a positive market outlook. This trend suggests growing confidence among investors, who appear to expect favorable performance from the stock.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


IPCALAB has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view IPCALAB as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.